Excerpt
The last decade has seen major advances in the care of patients with rheumatoid arthritis (RA). New therapeutics are available that significantly reduce disease activity, improve physical function, and reduce the damage to joints that, over time, can lead to disability. Further, studies such as the BeST study, the TICORA study, and others have convincingly demonstrated that systematic application of defined treatment strategies in the clinic setting can reduce disease activity to low levels in large proportions of patients1–4. Critical to accomplishing these important advances has been the development and refinement of measurement tools to accurately assess disease activity…
Footnotes
-
The views in this editorial do not necessarily reflect those of the US Food and Drug Administration.